About Aveo

AVEO Pharmaceuticals Science. Passion. Impact

 

AVEO is a biopharmaceutical company focused on discovering, developing and commercializing novel cancer therapeutics. Our product candidates are directed against important mechanisms, or targets, known or believed to be involved in cancer. Tivozanib, our lead product candidate, is a highly potent and selective oral inhibitor of the vascular endothelial growth factor, or VEGF, receptors 1, 2 and 3. Our clinical trials of tivozanib to date have demonstrated a favorable safety and efficacy profile for tivozanib.

In addition to tivozanib, we have a pipeline of monoclonal antibodies derived from our Human Response Platform (HRP™), a novel method of building preclinical models of human cancer, which are intended to more accurately represent cancer biology in patients. AV-299, our next most advanced product candidate, is an antibody which binds to hepatocyte growth factor, or HGF, thereby blocking its function.
 
 Traditional methods of modeling human cancer generally have not been able to accurately predict the success of drugs once they enter the clinic, and success rates for development of novel cancer drugs have historically been quite low. We believe that our HRP provides us with unique insights into cancer biology and mechanisms of drug response and resistance, and represents a significant improvement over traditional approaches. We are utilizing our HRP alone and with our strategic partners to:

• identify and validate target genes which drive tumor growth,
• evaluate drugs which can block the function of these targets and
• identify biomarkers, which are indicators of drug response and resistance in patients, in an effort to evaluate which patients are most likely to respond favorably to treatment with such drugs.

In addition, we have identified a number of other promising targets for the development of novel cancer therapeutics using our HRP. We have preclinical antibody discovery programs underway focusing on targets that appear to be important drivers of tumor growth, including the ErbB3 receptor (partnered with Biogen Idec), the RON receptor, the Notch receptors and the Fibroblast Growth Factor receptors.